

ASX ANNOUNCEMENT

Analytica reports half year results

28th February 2017: Brisbane, Australia - Analytica Ltd (ASX: ALT) manufacturer of the PeriCoach® System, today released its Appendix 4D – half year report for the six months ended 31st December 2016.

FINANCIAL RESULTS

- Net loss down 23% to \$939k
- Total revenue down 41% to \$1,199k
- Direct research and development costs \$945k down from \$1,259k
- Marketing and Market Research \$233k down from 1,069k
- Cash position at the end of the year: \$1,228k

Analytica has made excellent progress on delivery of the commitments outlined by the chairman at the 2015 AGM and reaffirmed at the 2016 AGM.

- Build best in class, first response pelvic floor treatment system
 - Major enhancements of system functionality as a result of clinical trial, post market surveys and in market feedback.
 - Ability to instruct women on proper technique
 - Deploy sophisticated data analysis system providing global insights into pelvic health.
 - PeriCoach V3 in production, on track to release Q2 2017
- Prove it works
 - Post clearance randomised controlled clinical trial provides independent evidence of effectiveness of PeriCoach system
 - Trial showed improvement in urinary incontinence, muscle strength and muscle rehabilitation.
 - Quality of life and sexual satisfaction scores much higher for PeriCoach users.
 - Trial not required for registration rather for marketing purposes
 - Clinical Trial concluded early with positive intragroup improvement from baseline in continence thus intergroup end point not met.
 - Abstracts on trial being well accepted at major urology and sexual health clinician conferences
 - Real world data collection with PeriCoach v3 to further demonstrate efficacy of product.
- Define the market
 - Baseline understanding of market drivers for adoption and commercialisation
 - Continued engagement with key opinion leaders and authoritative journals
- Do a deal.
 - FDA clearance for over the counter purchase by women in US
 - Accumulating protection of intellectual property around the world
 - Building deal development with expert advice and assistance



Capital.

- In the 6 months to December 2016, cornerstone investor contributed a further \$500k
- January announcement of capital placements of \$722k to non-related parties, a further placement of \$720k subject to shareholder approval with further \$60k placement in February, totals \$1.5m

"During the half year to December 2016, we continued to make progress towards our goal of establishing PeriCoach as the leading device for pelvic floor muscle training and the treatment of urinary incontinence and other pelvic floor muscle conditions," said Analytica CEO Geoff Daly.

"We continue to gather data in order to establish PeriCoach's credibility as a device that effectively treats women and continue to invest in R&D to ensure it remains best in class with the view of creating a positive sales environment for the system and ultimately securing a global sales partner."

"Analytica is a small, medical device research, development, and commercialisation company. This was my message at the previous two AGM's and has consistently been our message", said Dr Michael Monsour, chairman. "Analytica is developing the best in class medical device product, for pelvic floor conditions. To effectively market our products, PeriCoach and AutoStart Burette, requires partnership with large, resourced organisations, who require specific data which we continue to compile. That's what we said we would do and that's what we are doing. The opportunity to share our progress is governed by commerciality, regulatory and continuous disclosure requirements. Considering our resources, the progress has been remarkable."

For more information please contact investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product has been on sale in Australia and New Zealand since January, and recently launched in the UK and Ireland, and in the USA. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.

